Indications for XOFLUZA:
Acute uncomplicated influenza in patients who have been symptomatic for no more than 48hrs and who are otherwise healthy, or at high risk of developing influenza-related complications.
Limitations of Use:
Consider available information on drug susceptibility patterns for circulating influenza strains when deciding whether to use.
Start within 48hrs of symptom onset. ≥12yrs (40–<80kg): 40mg as a single dose; (≥80kg): 80mg as a single dose.
<12yrs (or <40kg): not established.
Potential secondary bacterial infections; treat appropriately. Pregnancy. Nursing mothers.
Polymerase acidic (PA) endonuclease inhibitor.
Avoid co-administration with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (eg, calcium, iron, magnesium, selenium, or zinc). May reduce efficacy of live attenuated influenza vaccines.
Diarrhea, bronchitis, nausea, sinusitis, headache; hypersensitivity reactions.